Clinical trials: Tremelimumab
Solid Tumor
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.
- Trial name
- NCT02718911
- Testing
- LY3022855, Durvalumab, Tremelimumab
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
This phase II trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment.
- Trial name
- NCT03373760
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Where
- 1,021 sites in United States
- Volunteers
- 67 people
- Sponsor
- SWOG Cancer Research Network
Renal Cell Carcinoma, Kidney Cancer
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
The purpose of this study is to investigate the safety and feasibility of administering investigational drugs (meaning not Food and Drug Administration (FDA)-approved for kidney cancer) prior to surgical treatment for kidney…
- Trial name
- NCT02762006
- Testing
- Durvalumab, Tremelimumab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Moshe Ornstein
Infiltrating Bladder Urothelial Carcinoma
NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma
This is an open label, phase I/II clinical trial to evaluate the efficacy and safety of 2 cycles of durvalumab without (Arm A) or with (Arm B) tremelimumab in association with ddMVAC as neoadjuvant therapy in patients with MIUC.
- Trial name
- NEMIO (NCT03549715)
- Testing
- Durvalumab, Tremelimumab, MVAC Protocol
- Where
- 15 sites in France
- Volunteers
- 121 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Part A and B: Advanced Solid Malignancies, Part C: Malignant Mesothelioma
Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, PK and Preliminary Anti-tumor Activity when given as a monotherapy of Tremelimumab or Tremelimumab in combination with MEDI4736 in Japanese Patients…
- Trial name
- NCT02141347
- Testing
- Tremelimumab, MEDI4736
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed…
- Trial name
- ADRIATIC (NCT03703297)
- Testing
- Durvalumab, Tremelimumab
- Where
- 183 sites in United States, Argentina and 17 more
- Volunteers
- 730 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients
This is an open-label phase 1, safety, PK, and preliminary efficacy study of oral Gefitinib and IV Tremelimumab in previously treated NSCLC patients who have documented evidence of an activating mutation in the EGFR gene and have…
- Trial name
- GEFTREM (NCT02040064)
- Testing
- Gefitinib, Tremelimumab
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
This phase I trial studies the side effects and best dose of belinostat when given together with durvalumab in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed…
- Conditions
- Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Trial name
- RESOLVE (NCT05154994)
- Testing
- Belinostat, Durvalumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Utah
Metastatic Carcinoma in the Liver, Resectable Mass
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
This phase I trial studies the side effects and how well tremelimumab and durvalumab work in treating patients with colorectal cancer that has spread to the liver and can be removed by surgery.
- Conditions
- Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT02754856
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies the safety, tolerability and how well durvalumab and tremelimumab work in treating participants with castration-resistant prostate cancer who have not received chemotherapy (chemotherapy naïve) and has…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT03204812
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Ovarian Cancer
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
This was a Phase 1, open-label, nonrandomized, multicenter study of durvalumab and tremelimumab in subjects with advanced cancers who were not eligible for, declined, or failed standard treatment.
- Conditions
- Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer
- Trial name
- NCT01975831
- Testing
- Durvalumab, Tremelimumab
- Where
- 6 sites in United States
- Volunteers
- 104 people
- Sponsor
- Ludwig Institute for Cancer Research
Malignant Glioma, Recurrent Glioblastoma
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
The main purpose of this trial is to investigate the effects of a new class of drugs that help the patient's immune system attack their tumor (glioblastoma multiforme - GBM).
- Trial name
- NCT02794883
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Surgical Procedure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwestern University
Urothelial Bladder Cancer, Triple-negative Breast Cancer
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
- Conditions
- Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT02527434
- Testing
- Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Cancer, Rare Disease
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
This is an investigator initiated single institution, open-label study to evaluate the antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab in subjects with select advanced rare solid tumors.
- Trial name
- NCT02938793
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Prisma Health-Upstate
Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
This phase I trial studies how well stereotactic body radiation therapy works in combination with tremelimumab and durvalumab in treating participants with cervical, vaginal, or vulvar cancers that have come back (recurrent) or…
- Conditions
- Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
- Trial name
- NCT03452332
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer Metastatic
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Durvalumab is a new type of drug for many kinds of cancer. It is considered "immunotherapy" and not "chemotherapy". Laboratory tests show that it works by allowing the immune system to detect cancer and reactivate the immune…
- Trial name
- NCT03057106
- Testing
- Durvalumab, Tremelimumab, Platinum-Based Drug
- Where
- 49 sites in Australia, Canada
- Volunteers
- 301 people
- Sponsor
- Canadian Cancer Trials Group
Hepatocellular Carcinoma Non-resectable, HCC
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
- Trial name
- IMMUWIN (NCT04522544)
- Testing
- Tremelimumab, Durvalumab, Y-90 SIRT
- Where
- 11 sites in Germany
- Volunteers
- 55 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma (HCC)
A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
This is an early-phase study testing a new combination treatment for cancer. participants will receive a type of radiation therapy called MRI-guided or CT-guided radiotherapy, depending on which imaging method is safe for them.
- Trial name
- PRISM (NCT06994299)
- Testing
- Radiation Therapy, Tremelimumab, Durvalumab
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Gastric Cancer, Esophageal Adenocarcinoma
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies.
- Conditions
- Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- CAMILLA (NCT03539822)
- Testing
- Cabozantinib, Durvalumab, Tremelimumab
- Where
- 2 sites in United States
- Volunteers
- 117 people
- Sponsor
- Anwaar Saeed
HCC - Hepatocellular Carcinoma, Tremelimumab
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, Radiotherapy
- Trial name
- Photon-STRIDE (NCT06999707)
- Testing
- Photon radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital